Motor Control Exercises and Neural Mobilization in Posture of Older Adults

April 11, 2022 updated by: Riphah International University

Effects of Motor Control Exercises With and Without Neural Mobilization on Postural Control of Older Adults

The aim of this research is to find and compare the effect of Motor control exercises with and without neural mobilization on postural control of older adults.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Randomized controlled trials done at Bilqees Eidhi and Afiyat old age home Lahore.The sample size was 40. The subjects were divided in two groups, 20 subjects in Motor control exercise group and 20 in Motor control exercise with neural gliding group. Study duration was of 6 months. Sampling technique applied was purposive non probability sampling technique. Only 65-80 years of older adults included in study. Tools used in the study are time up and go test(TUG), Gait speed, Static balance and Quality of life(OPQOL35). Data was analyzed through SPSS 21.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Binash Afzal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

60 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Both male and female were included
  • Older adults having age range from 60-80 years or older
  • Adults whose score is more than 24 on mini mental state examination.
  • Ambulate independently with or without a walking aid
  • Adults who had permission from the institution's doctor to participate in exercise classes.

Exclusion Criteria:

  • Patients with altered conscious level
  • Adults who cannot ambulate (bed ridden patients)
  • Patient with any neurological condition like stroke, multiple sclerosis and TBI
  • Patients with severe orthopedic condition like fractures and rheumatoid arthritis
  • Patient having any cardiac condition
  • Adults walking with walking aids like sick and crutches
  • Adults having vertigo or vestibular problems.
  • Adults having history of recurrent falls.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Motor control exercise
Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
Other: Motor control exercise
Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
Active Comparator: Motor control exercise with neural mobilization
this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
Other: Motor control exercise with mobilization
this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Static balance test
Time Frame: first reading at 0 week
Balance will be assessed using the Tandem stance (TS) test for static balance. The intraobserver reliability of the test is good with an ICC of 0.80.
first reading at 0 week
Static balance test
Time Frame: final reading at end of 4 week
Balance will be assessed using the Tandem stance (TS) test for static balance. The intraobserver reliability of the test is good with an ICC of 0.80.
final reading at end of 4 week
Gait speed test
Time Frame: first reading at 0 week
The 4-m gait speed test will use, and the beginning and the end of the test will mark on the floor. The intra-observer reliability of the gait speed test is excellent with an ICC of 0.91, a standard error of measurement of 0.06 m/s, and a minimum detectable difference (MDD) of 0.17 m/s.
first reading at 0 week
Gait speed test
Time Frame: final reading at end of 4 week
The 4-m gait speed test will use, and the beginning and the end of the test will mark on the floor. The intra-observer reliability of the gait speed test is excellent with an ICC of 0.91, a standard error of measurement of 0.06 m/s, and a minimum detectable difference (MDD) of 0.17 m/s.
final reading at end of 4 week
Timed Up and Go test
Time Frame: first reading at 0 week
Timing began when participants initiate standing and end when they sat down. The mean of the measurements will be use for statistical purposes. The inter-observer reliability is good with an ICC of 0.89, a standard error of measurement of 3.99 seconds, and an MDD of 11.06 seconds.
first reading at 0 week
Timed Up and Go test
Time Frame: final reading at 4 week
Timing began when participants initiate standing and end when they sat down. The mean of the measurements will be use for statistical purposes. The inter-observer reliability is good with an ICC of 0.89, a standard error of measurement of 3.99 seconds, and an MDD of 11.06 seconds.
final reading at 4 week
Quality of life: (OPQOL 35)
Time Frame: first reading at 0 week
OPQOL questionnaire, has been validated in a multiethnic community-dwelling older population in England. Cronbach's alpha coefficient for the Italian outpatient population enrolled in this study was found to be 0.78, i.e. above the 0.70 threshold of acceptability for internal consistency.
first reading at 0 week
Quality of life: (OPQOL 35)
Time Frame: final reading at 4 week
OPQOL questionnaire, has been validated in a multiethnic community-dwelling older population in England. Cronbach's alpha coefficient for the Italian outpatient population enrolled in this study was found to be 0.78, i.e. above the 0.70 threshold of acceptability for internal consistency.
final reading at 4 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 15, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 15, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 21, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 11, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 19, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 19, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 11, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RiphahIU Raana Rubab

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings